New combo therapy targets tough pancreatic cancer
NCT ID NCT03080974
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 26 times
Summary
This study tests a new treatment for people with advanced pancreatic cancer that has not spread to other organs. It combines a drug that helps the immune system fight cancer (Nivolumab) with a procedure that uses electrical pulses to destroy tumor cells (irreversible electroporation). The goal is to see if this combination is safe and can help people live longer. The study is currently recruiting 10 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Louisville
RECRUITINGLouisville, Kentucky, 40202, United States
Conditions
Explore the condition pages connected to this study.